A central question facing ICER and CVS Caremark is whether a drug’s value should depend on not only a measure such as QALYs, but also on which disease or population is being treated, which implies that a QALY may not always have the same weight.
A central question facing ICER and CVS Caremark is whether a drug’s value should depend on not only a measure such as QALYs, but also on which disease or population is being treated, which implies that a QALY may not always have the same weight.